Parabilis reports Q2 2026 results, $1.1B cash, Regeneron pact

Parabilis Medicines reported second quarter 2026 financial results and business updates on August 13, 2026, for the period ended June 30, 2026.

The company said it expanded its executive leadership team through the appointments of Helen Ho, Ph.D., as Chief Business & Strategy Officer, and Tom Kotarakos as Chief Financial Officer¹, and appointed Alan M. Sebulsky to the Board of Directors¹.

On its lead program, Parabilis said an abstract was accepted for oral presentation at the ESMO Congress 2026 in Madrid (Oct. 23-27), with plans to share clinical data from a February data cut from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients¹. The company also said it expects to present more mature Phase 1/2 data in desmoid tumors during the fourth quarter of 2026, engage the FDA that same quarter on the planned registrational Phase 3 trial, and remains on track to initiate the Phase 3 trial in the first half of 2027¹.

In its Regeneron collaboration, Parabilis said it received $125 million, including $50 million in upfront consideration and a $75 million equity investment, with potential for up to approximately $2.2 billion in milestone payments plus up to low double-digit tiered royalties¹.

Financially, the company closed an upsized initial public offering at $20.00 per share, including full exercise of the underwriters' option, and began trading on Nasdaq under "PBLS" on June 10, 2026¹. Cash, cash equivalents and marketable securities were $1.1 billion as of June 30, 2026, compared to $27.7 million as of December 31, 2025, expected to fund operations into 2030¹.

R&D expenses were $39.4 million for the quarter, compared to $30.1 million a year earlier¹, while net loss was $52.5 million, compared to $34.8 million in the prior year period¹.